Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Quiflapon sodium (MK591) is a selective inhibitor of 5-Lipoxygenase-activating protein (FLAP).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
2 mg | 約 5 days | ¥ 19,500 |
50 mg | 約6-8 週間 | ¥ 171,500 |
100 mg | 約6-8 週間 | ¥ 228,500 |
In vivo | In hyperoxia-exposed mice, treatment with Quiflapon sodium (20, 40 mg/kg) resulted in alveolar development similar to that observed in mice breathing room air, in contrast to untreated hyperoxia-exposed mice which exhibited altered alveolarization without inflammation [3]. Treatment with Quiflapon sodium (320 mg/kg) significantly reduced amyloid accumulation in the brain compared to placebo-treated mice. Additionally, Quiflapon sodium effectively decreased brain levels of IL-1β and led to a significant reduction in both total and phosphorylated Ser133 CREB levels [4]. |
別名 | MK591 |
分子量 | 610.16 |
分子式 | C34H35ClN2NaO3S |
CAS No. | 147030-01-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 50 mg/mL (82.08 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Quiflapon sodium 147030-01-1 Immunology/Inflammation FLAP MK 591 MK591 MK-591 Inhibitor inhibitor inhibit